SBC Medical Group (SBC) Projected to Post Quarterly Earnings on Friday

SBC Medical Group (NASDAQ:SBC) is projected to release its Q3 2025 results before the market opens on Friday, November 14th. Analysts expect SBC Medical Group to post earnings of $0.13 per share and revenue of $46.4490 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 17, 2025 at 5:00 PM ET.

SBC Medical Group (NASDAQ:SBC) last announced its quarterly earnings results on Wednesday, August 13th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.12). The firm had revenue of $43.36 million for the quarter, compared to analysts’ expectations of $44.71 million. SBC Medical Group had a return on equity of 20.76% and a net margin of 17.71%. On average, analysts expect SBC Medical Group to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

SBC Medical Group Stock Performance

SBC Medical Group stock opened at $3.08 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.95 and a current ratio of 3.98. The company has a market capitalization of $319.95 million, a price-to-earnings ratio of 9.63 and a beta of 1.27. SBC Medical Group has a fifty-two week low of $2.62 and a fifty-two week high of $7.99. The stock has a fifty day moving average of $4.09 and a two-hundred day moving average of $4.23.

Analyst Upgrades and Downgrades

SBC has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SBC Medical Group in a research report on Tuesday, October 14th. Maxim Group assumed coverage on SBC Medical Group in a report on Wednesday. They issued a “buy” rating and a $9.00 price target for the company. Finally, Wall Street Zen upgraded shares of SBC Medical Group from a “hold” rating to a “buy” rating in a research note on Saturday, September 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SBC Medical Group currently has an average rating of “Hold” and a consensus target price of $9.00.

Institutional Trading of SBC Medical Group

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC acquired a new position in shares of SBC Medical Group in the 2nd quarter valued at $455,000. New York State Common Retirement Fund purchased a new stake in SBC Medical Group during the 2nd quarter worth about $104,000. Finally, XTX Topco Ltd purchased a new stake in SBC Medical Group in the 2nd quarter valued at about $64,000. 60.82% of the stock is currently owned by hedge funds and other institutional investors.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand.